Prostate Cancer
OGX-011 for Metastatic Castrate Resistant Prostate Cancer (SYNERGY)
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Investigator: Celestia S. Higano, MD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT01188187
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy (RTOG 0534)
Investigator: George Laramore, MD, PhD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT00567580
A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy
Investigator: Dr. Celestia S. Higano; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT01212991
A Randomized Phase II Study of OGX-427 (a Second-Generation Antisense Oligonucleotide to Heat Shock Protein-27) in Patients With Castration Resistant Prostate Cancer Who Have Not Previously Received Chemotherapy for Metastatic Disease
Investigator: Evan Ya-Wen Yu, MD; Conditions: Castration Resistant Prostate Cancer; Status: Recruiting; Study ID: NCT01120470
A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone
Investigator: Fred Appelbaum, MD; Conditions: Metastatic Cancer, Prostate Cancer; Status: Recruiting; Study ID: NCT00079001
Phase II Trial of Abiraterone Acetate Combined with Dutasteride with Correlative Assessment of Tumor Androgen Levels and Androgen Receptor Signaling in Patients with Metastatic Castrate Resistant Prostate Cancer (CRPC)
Investigator: Robert Montgomery, MD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT01393730
An Open-Label, Phase 1/2, Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Patients With Progressive Advanced Castration-Resistant Prostate Cancer
Investigator: Celestia S. Higano, MD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT01171898
Molecular correlates of sensitivity and resistance to therapy in prostate cancer
Investigator: Robert Montgomery, MD; Conditions: Metastatic Prostate Cancer; Status: Recruiting; Study ID: NCT01050504
Canary Prostate Active Surveillance Study
Investigator: Daniel W. Lin, MD; Conditions: Prostatic Neoplasms; Status: Recruiting; Study ID: NCT00756665
SCORE -- Assessment of Mood, Information Processing and Quality of Life in Prostate Cancer Survivors and Patients
Investigator: Monique Cherrier, PhD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: 30824
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
Investigator: Dr. Celestia S. Higano; Conditions: Advanced Solid Tumors; Status: Recruiting; Study ID: NCT00940225
A Randomized Phase II Study of Intermittent Chemotherapy or Intermittent Chemotherapy with Maintenance GM-CSF in Patients with Previously Untreated Metastatic Hormone Refractory Prostate Cancer
Investigator: Tia Higano, MD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT00488982
A Randomized Phase II Study of Combined Androgen Deprivation Versus Combined Androgen Deprivation with IMC-A12 for Patients with New Hormone Sensitive Metastatic Prostate Cancer
Investigator: Evan Yu, MD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT01120236
Phase 2 Trial of Radiation with Androgen Deprivation (RAD): Abiraterone Acetate, Prednisone and LHRH Agonist Prior to and Concurrent with Radiation Therapy.
Investigator: Robert Montgomery, MD; Conditions: Prostate Cancer, Adenocarcinoma of the Prostate, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer; Status: Recruiting; Study ID: NCT01023061
Intermittent Hormone Therapy in Men with Localized Prostate Cancer who Have Biochemical Relapse After External Beam Irradiation or Radical Prostatectomy
Investigator: Tia Higano, MD; Conditions: Genitourinary Cancer; Prostate Cancer; Solid Tumors; Status: Recruiting; Study ID: NCT00223665
A Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, or No MLN8237 in Patients with Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel/Prednisone Regimen, Preceded by a Phase I Dose-Escalation Study - Part 1 and 2
Investigator: Tia Higano, MD; Conditions: Genitourinary Cancer; Prostate Cancer; Solid Tumors; Status: Recruiting; Study ID: NCT01094288
A Phase 1 Study of ABT-888 (Veliparib) in Combination With Carboplatin (Paraplatin) and Gemcitabline (Gemzar) in Subjects With Advanced Solid Tumors
Investigator: Heidi J. Gray, MD; Conditions: Advanced Solid Tumors; Status: Not Recruiting; Study ID: NCT01063816
An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
Investigator: John Thompson, MD; Conditions: Advanced Non-Hematologic Malignancies, Non Small Cell Lung Cancer, Head and Neck Cancer, Soft Tissue Sarcoma, Prostate Cancer; Status: Closed/Not Recruiting; Study ID: NCT00830869
Join Us On